MND / ALS
Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for Disease Control and Prevention. The rapidly progressing neurodegenerative disease causes the death of neurons in the brain and spinal cord, resulting in muscle weakness, [...]
A pioneering study has revealed promising results for a new treatment targeting motor neurone disease (MND). The novel drug compound, Ellorarxine, developed by Nevrargenics, has demonstrated significant potential in improving neuronal health and nervous system regeneration in MND sufferers. The study has shown that Ellorarxine exhibits antioxidant and anti-inflammatory effects at remarkably low concentrations. One of [...]
HRH the Princess Royal has underlined the importance of collaboration in the search for a motor neurone disease cure. The royal was speaking at the MND Association’s Countdown to a Cure reception, held this week in London. The event was an opportunity to reflect on the charity's support for MND research and how some of its [...]
A new campaign is aiming to help more people living with motor neurone disease (MND) to access a ground-breaking drug. UK charity the MND Association has launched the Prescribe Life campaign and is urging the National Institute for Health and Care Excellence (NICE) to use its discretionary powers to evaluate the drug tofersen in the [...]
Experts from the University of Nottingham have worked with people living with Motor Neurone Disease (MND), to share personal stories for other people with MND who want to understand what it is like to live with tracheostomy ventilation (TV). As part of a major study, Dr Eleanor Wilson and Dr Nicola Turner in the School [...]
The ALS Network, formerly ALS Golden West, has awarded a $100,000 grant through its global research programme to Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. The San Diego-based diagnostics company seeks to understand the cause of sporadic ALS and actively assists in the development of potential therapies by supporting [...]
A highly accurate diagnostic blood test has been developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease. ALS/MND leads to gradual paralysis, ultimately resulting in the inability to walk, speak, or, in later stages, move. Currently, diagnosis is based on a thorough clinical examination, but it can take up to [...]
NRG Therapeutics, a neuroscience company targeting mitochondrial dysfunction, has been awarded a non-dilutive grant from Target ALS Foundation to support the development of mPTP inhibitors as novel treatments for for Amyotrophic Lateral Sclerosis (ALS [also known as Lou Gehrig’s disease or Motor Neurone Disease]). The company is one of five recipients of the 2024 In [...]
Pathological abnormalities associated with motor neurone disease (MND) have been identified using a new technique developed at the University of Birmingham. The method will help scientists better understand the changes in the brain that lead to MND and could eventually yield insights that will help with the development of new treatments. The abnormalities were identified [...]
A new initiative is aiming to accelerate motor neurone disease research by harnessing the power of health data. The MND Research Data Catalyst is a new initiative led by HDR UK and DPUK, with the UK Dementia Research Institute (UK DRI) and in partnership with the MND research community, to accelerate the discovery of new [...]
